Literature DB >> 12082550

Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.

Jim Dimitroulakos1, Wilson H Marhin, Jason Tokunaga, Jonathan Irish, Patrick Gullane, Linda Z Penn, Suzanne Kamel-Reid.   

Abstract

We recently identified 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of the mevalonate pathway, as a potential therapeutic target of the head and neck squamous cell carcinomas (HNSCC) and cervical carcinomas (CC). The products of this complex biochemical pathway, including de novo cholesterol, are vital for a variety of key cellular functions affecting membrane integrity, cell signaling, protein synthesis, and cell cycle progression. Lovastatin, a specific inhibitor of HMG-CoA reductase, induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC. The mediators of this response are not well established. Identification of differentially expressed genes represents a feasible approach to delineate these mediators as lovastatin has the potential to modulate transcription indirectly by perturbing levels of sterols and other mevalonate metabolites. Expression analysis following treatment of the HNSCC cell lines SCC9 or SCC25 with 10 microM lovastatin for 1 day showed that less than 2% (9 cDNAs) of the 588 cDNAs on this microarray were affected in both cell lines. These included diazepam-binding inhibitor/acyl-CoA-binding protein, the activated transcription factor 4 and rhoA. Because the biosynthesis of mevalonate leads to its incorporation into more than a dozen classes of end products, their role in lovastatin-induced apoptosis was also evaluated. Addition of the metabolites of all the major branches of the mevalonate pathway indicated that only the nonsterol moiety, geranylgeranyl pyrophosphate (GGPP), significantly inhibited the apoptotic effects of lovastatin in HNSCC and CC cells. Because rhoA requires GGPP for its function, this links the microarray and biochemical data and identifies rhoA as a potential mediator of the anticancer properties of lovastatin. Our data suggest that the depletion of nonsterol mevalonate metabolites, particularly GGPP, can be potential mediators of lovastatin-induced apoptosis of HNSCC and CC cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082550      PMCID: PMC1531704          DOI: 10.1038/sj.neo.7900247

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  42 in total

Review 1.  Genomics and proteomics: the new millennium of drug discovery and development.

Authors:  M J Cunningham
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Jul-Aug       Impact factor: 1.950

Review 2.  Biochip technologies in cancer research.

Authors:  O P Kallioniemi
Journal:  Ann Med       Date:  2001-03       Impact factor: 4.709

Review 3.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

4.  Characterization of human activating transcription factor 4, a transcriptional activator that interacts with multiple domains of cAMP-responsive element-binding protein (CREB)-binding protein.

Authors:  G Liang; T Hai
Journal:  J Biol Chem       Date:  1997-09-19       Impact factor: 5.157

5.  Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.

Authors:  T Kusama; M Mukai; T Iwasaki; M Tatsuta; Y Matsumoto; H Akedo; H Nakamura
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

Review 6.  The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis.

Authors:  T Hai; M G Hartman
Journal:  Gene       Date:  2001-07-25       Impact factor: 3.688

Review 7.  Ras and Rho regulation of the cell cycle and oncogenesis.

Authors:  K Pruitt; C J Der
Journal:  Cancer Lett       Date:  2001-09-28       Impact factor: 8.679

Review 8.  Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.

Authors:  S M Sebti; A D Hamilton
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

9.  Lovastatin induces a pronounced differentiation response in acute myeloid leukemias.

Authors:  J Dimitroulakos; S Thai; G H Wasfy; D W Hedley; M D Minden; L Z Penn
Journal:  Leuk Lymphoma       Date:  2000-12

10.  Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

Authors:  Z Xia; M M Tan; W W Wong; J Dimitroulakos; M D Minden; L Z Penn
Journal:  Leukemia       Date:  2001-09       Impact factor: 11.528

View more
  31 in total

1.  Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality.

Authors:  Aaron P Thrift; Yamini Natarajan; Yan Liu; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-06       Impact factor: 11.382

2.  CAAX-box protein, prenylation process and carcinogenesis.

Authors:  Juehua Gao; Jie Liao; Guang-Yu Yang
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

3.  In vitro Anti-Tumor Effects of Statins on Head and Neck Squamous Cell Carcinoma: A Systematic Review.

Authors:  Ludmila Madeira Cardoso Pavan; Daniela Fortunato Rêgo; Silvia Taveira Elias; Graziela De Luca Canto; Eliete Neves Silva Guerra
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

4.  Do statins reduce patients' risk of hepatocellular carcinoma?

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-05

Review 5.  The effects of statins on dental and oral health: a review of preclinical and clinical studies.

Authors:  Shabnam Tahamtan; Farinaz Shirban; Mohammad Bagherniya; Thomas P Johnston; Amirhossein Sahebkar
Journal:  J Transl Med       Date:  2020-04-06       Impact factor: 5.531

Review 6.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

Review 7.  Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials.

Authors:  Xiao-long Zhang; Min Liu; Jian Qian; Jun-hua Zheng; Xiao-peng Zhang; Chang-cheng Guo; Jiang Geng; Bo Peng; Jian-ping Che; Yan Wu
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

8.  Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.

Authors:  Angela J Mantha; Kathryn E McFee; Nima Niknejad; Glenwood Goss; Ian A Lorimer; Jim Dimitroulakos
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-26       Impact factor: 4.553

9.  Laser capture microdissection and genetic analysis of carbon-labeled Kupffer cells.

Authors:  Stephan Gehring; Edmond Sabo; Maryann E San Martin; Elizabeth M Dickson; Chao-Wen Cheng; Stephen H Gregory
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

10.  Identification of triosephosphate isomerase as an anti-drug resistance agent in human gastric cancer cells using functional proteomic analysis.

Authors:  Xin Wang; Yuanyuan Lu; Jinghua Yang; Yongquan Shi; Mei Lan; Zhenxiong Liu; Huihong Zhai; Daiming Fan
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-29       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.